Loading
The head-to-head trial in which furmonertinib nearly doubled the time before lung cancer grew compared with gefitinib, mirroring FLAURA with a Chinese drug.
358 patients, double blind. Median progression-free survival 20.8 versus 11.1 months (hazard ratio 0.44), with strong central nervous system activity and a tolerable safety profile. NMPA first-line approval June 2022. With AENEAS it gave China two domestic third-generation EGFR inhibitors competing with osimertinib on price after NRDL listing.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Shanghai Chest Hospital, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag china.
Shares AENEAS, EGFR, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag china.
Shares EGFR, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag china.
Shares EGFR, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag china.
Shares EGFR, Non-small-cell lung cancer and the tag china.
Shares Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag china.
Shares Non-small-cell lung cancer and the tag china.
Shares Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag china.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/